The left ventricular assist device (LVAD) wars are now a bit more interesting with the news that the FDA has approved the Heartmate 3 device for destination therapy, pitting Abbott Laboratories, of Abbott Park, Ill., against Medtronic plc, of Dublin, and its Heartware VAD. Medtronic beat Abbott to the destination therapy indication via an FDA approval in September 2017. However, at least one analyst sees a global sales jump for Abbott in excess of $200 million over the next two years, abetted principally by the FDA approval.